dabrafenib: Clinical Trials

90 trials of dabrafenib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

29 completed, 18 recruiting, 15 active not recruiting, 10 terminated. 90 Phase 2, 17 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 290Completed 29, Recruiting 18, Active not recruiting 15, Terminated 10, Unknown 9, Withdrawn 6, Not yet recruiting 3
Phase 117Completed 9, Active not recruiting 4, Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1
Phase 33Recruiting 2, Not yet recruiting 1

Follow dabrafenib: new trials by email Literature Review of dabrafenib trials Research Report on dabrafenib

Trials (filtered) newest first · largest first

All 90 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid Cancer
Dabrafenib, Trametinib, Pembrolizumab - Anaplastic Thyroid Carcinoma, Thyroid Cancer
Phase 2Not yet recruitingWashington University School of Medicine122026-12-312026-10-21
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm
Phase 2 / Phase 3RecruitingCancer Research UK302026-04-012026-08-17
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
Ipilimumab N01, Sintilimab, Cetuximab - BRAF V600E, Colorectal Cancer
Phase 2RecruitingTianjin Medical University Cancer Institute and Hospital492026-03-012026-04-07
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
Dabrafenib, Trametinib, Magnetic Resonance Imaging (MRI) - BRAF V600 Mutation, Low-grade Glioma
Phase 2RecruitingUniversity of California, San Francisco962025-11-072026-10-26
Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children
Dabrafenib or Trametinib and Clofarabine - Langerhans Cell Histiocytosis (LCH)
Phase 2RecruitingWest China Second University Hospital202025-06-012025-06-15
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
Trametinib and Nivolumab, Dabrafenib, trametinib, nivolumab - Low Grade Glioma, High Grade Glioma
Phase 1 / Phase 2RecruitingAnn & Robert H Lurie Children's Hospital of Chicago272025-04-012026-07-10
Precision Cancer Therapy in Rare Cancers
Imatinib, Trametinib, Dabrafenib - Rare Malignant Neoplasm
Phase 2RecruitingOslo University Hospital962025-03-202025-03-26
A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer
mFOLFOX6 + dabrafenib and cetuximab or panitumumab in the first line of therapy - Neoplasms
Phase 2RecruitingBlokhin's Russian Cancer Research Center642025-03-012025-05-18
Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma
Dabrafenib and trametinib (combination) - Ameloblastoma
Phase 2 / Phase 3Not yet recruitingShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University462025-03-012025-02-11
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Olaparib tablet, Temozolomide capsule, Anlotinib - Solid Tumor, Precision Medicine
Phase 2RecruitingTianjin Medical University Second Hospital3002024-11-012024-12-18
Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
Dabrafenib + Trametinib - Anaplastic Thyroid Cancer
Phase 2UnknownSaint Petersburg State University, Russia102024-03-252024-04-12
Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations
Dabrafenib + Trametinib, Capmatinib - NSCLC, BRAF V600 Mutation
Phase 2Not yet recruitingSun Yat-sen University402024-02-012023-10-10
Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma
Oral dabrafenib and trametinib - Craniopharyngioma
Phase 2RecruitingEva Marie Erfurth, MD, PhD252023-09-012024-02-14
Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations
Dabrafenib, Trametinib - Cancer
Phase 2UnknownSe Jun Park302023-06-202023-11-30
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
Alectinib, Atezolizumab, Entrectinib - Haematological Malignancy, Solid Tumour
Phase 2 / Phase 3RecruitingCancer Research UK8252023-03-012026-07-01
Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
Dabrafenib, Trametinib - Ameloblastoma, BRAF V600E Mutation Positive
Phase 2RecruitingShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University122023-01-012024-10-22
NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)
dabrafenib/trametinib - Anaplastic Thyroid Cancer
Phase 2RecruitingLeiden University Medical Center202023-01-012023-10-12
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
IMM-1-104 Monotherapy (Treatment Group A), IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B), IMM-1-104 + modified FOLFIRINOX (Treatment Group C) - Advanced Solid Tumor, Pancreatic Adenocarcinoma
Phase 1 / Phase 2Active not recruitingImmuneering Corporation2092022-10-312026-10-20
A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)
Dabrafenib 75 MG, Trametinib 2 MG - Thyroid Cancer
Phase 2UnknownOlivia Newton-John Cancer Research Institute802022-07-142023-10-31
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Alectinib, Cobimetinib, Vismodegib - Advanced Cancer, Solid Tumor
Phase 2RecruitingHelsinki University Central Hospital2502021-12-102026-11-10

Showing 20 of 90. Sign in to see all of them.

Conditions studied

Melanoma (40)  ·  Neoplasms (15)  ·  Thyroid Carcinoma, Anaplastic (8)  ·  Thyroid Neoplasms (8)  ·  Brain Neoplasms (7)  ·  Glioma (7)  ·  Colorectal Neoplasms (6)  ·  Hematologic Neoplasms (6)  ·  Carcinoma, Non-Small-Cell Lung (5)  ·  Multiple Myeloma (5)  ·  Neoplasm Metastasis (5)  ·  Ameloblastoma (3)  ·  Histiocytosis, Langerhans-Cell (3)  ·  Skin Neoplasms (3)  ·  Thyroid Cancer, Papillary (3)

Sponsors

Novartis Pharmaceuticals (11)  ·  National Cancer Institute (NCI) (8)  ·  GlaxoSmithKline (5)  ·  M.D. Anderson Cancer Center (5)  ·  Memorial Sloan Kettering Cancer Center (3)  ·  Universitair Ziekenhuis Brussel (3)  ·  Cancer Research UK (2)  ·  Massachusetts General Hospital (2)  ·  Melanoma Institute Australia (2)  ·  Oslo University Hospital (2)  ·  Saint Petersburg State University, Russia (2)  ·  Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (2)  ·  The Netherlands Cancer Institute (2)  ·  University of California, San Francisco (2)  ·  Abramson Cancer Center at Penn Medicine (1)

Countries

United States (44)  ·  Australia (12)  ·  France (12)  ·  Germany (10)  ·  China (9)  ·  Italy (9)  ·  United Kingdom (8)  ·  Belgium (7)  ·  Canada (7)  ·  Netherlands (7)  ·  Spain (7)  ·  Japan (5)  ·  Norway (5)  ·  Denmark (4)  ·  Russia (4)

Top investigators

Rodabe N Amaria (2)  ·  Ahmad Awada, PhD (1)  ·  Alain Algazi, MD (1)  ·  Alain P Algazi (1)  ·  Alan L Ho, MD, PhD (1)  ·  Alexander Colevas (1)  ·  Andrew M Scott, MD, FRACP (1)  ·  Anne Hansen Ree, Prof. MD PhD (1)  ·  Antoni Ribas (1)  ·  Arjun Sahgal (1)  ·  Ashley Plant-Fox, MD (1)  ·  Bart Neyns, MD PhD (1)  ·  Bart Neyns, MD, PhD (1)

Results publications

PMID 34331515, PMID 36884302, PMID 24408395, PMID 26446943, PMID 36648215, PMID 37219859, PMID 37934000, PMID 15049016, PMID 18623218, PMID 19731321, PMID 23255383, PMID 23589673, PMID 23645591, PMID 24983357, PMID 25092772, PMID 25287827, PMID 25797743, PMID 26194764, PMID 26340744, PMID 26392102, PMID 26586415, PMID 26811525, PMID 27080216, PMID 27124486, PMID 27223498, PMID 27283860, PMID 27864013, PMID 28268064, PMID 28592387, PMID 28919011, PMID 28991513, PMID 29072975, PMID 29263218, PMID 29361468, PMID 29880583, PMID 30121602, PMID 30661097, PMID 31085763, PMID 31171444, PMID 31171878, PMID 31171879, PMID 31506385, PMID 31513482, PMID 31811016, PMID 31864178, PMID 32106306, PMID 32208873, PMID 32463741, PMID 32534242, PMID 32818466

NIH funding

U10CA180820 (3), 2015 (2), 2016 (2), U10CA032102 (2), U10CA180888 (2), U24CA196172 (2), 2017 (1), 2019 (1), 2023 (1), P30CA016672 (1), U01CA062490 (1), U01CA132194 (1), U10CA180830 (1), U10CA180886 (1), UM1CA081457 (1)